This trial has completed recruitment on this platform, and is no longer accepting new referrals.
The mRNA-1010-P301 clinical trial is evaluating the safety and immune response of an investigational vaccine that may protect against seasonal influenza (flu). The investigational mRNA-1010 vaccine is being compared to a currently available licensed flu vaccine. All participants will receive either the investigational mRNA-1010 vaccine or the currently available licensed flu vaccine.
Flu is estimated to cause 3 to 5 million cases of severe illness and up to 650,000 deaths each year. Current flu vaccinations rarely exceed 60% overall effectiveness.
mRNA-1010 is an investigational flu vaccine, based on mRNA technology.
Sites are located in the cities/states identified with the red pin:
Participation in this clinical trial lasts up to 13 months and includes phone calls and visits to the trial site.
Insurance is not needed to join this clinical trial, and travel expenses will be reimbursed.